207 related articles for article (PubMed ID: 19833728)
1. Pivotal role of the C-terminal DW-motif in mediating inhibition of pyruvate dehydrogenase kinase 2 by dichloroacetate.
Li J; Kato M; Chuang DT
J Biol Chem; 2009 Dec; 284(49):34458-67. PubMed ID: 19833728
[TBL] [Abstract][Full Text] [Related]
2. Marked differences between two isoforms of human pyruvate dehydrogenase kinase.
Baker JC; Yan X; Peng T; Kasten S; Roche TE
J Biol Chem; 2000 May; 275(21):15773-81. PubMed ID: 10748134
[TBL] [Abstract][Full Text] [Related]
3. Distinct structural mechanisms for inhibition of pyruvate dehydrogenase kinase isoforms by AZD7545, dichloroacetate, and radicicol.
Kato M; Li J; Chuang JL; Chuang DT
Structure; 2007 Aug; 15(8):992-1004. PubMed ID: 17683942
[TBL] [Abstract][Full Text] [Related]
4. Pyruvate dehydrogenase kinase-4 structures reveal a metastable open conformation fostering robust core-free basal activity.
Wynn RM; Kato M; Chuang JL; Tso SC; Li J; Chuang DT
J Biol Chem; 2008 Sep; 283(37):25305-25315. PubMed ID: 18658136
[TBL] [Abstract][Full Text] [Related]
5. Suppression of Pyruvate Dehydrogenase Kinase by Dichloroacetate in Cancer and Skeletal Muscle Cells Is Isoform Specific and Partially Independent of HIF-1α.
Škorja Milić N; Dolinar K; Miš K; Matkovič U; Bizjak M; Pavlin M; Podbregar M; Pirkmajer S
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445316
[TBL] [Abstract][Full Text] [Related]
6. Differential inhibition of PDKs by phenylbutyrate and enhancement of pyruvate dehydrogenase complex activity by combination with dichloroacetate.
Ferriero R; Iannuzzi C; Manco G; Brunetti-Pierri N
J Inherit Metab Dis; 2015 Sep; 38(5):895-904. PubMed ID: 25601413
[TBL] [Abstract][Full Text] [Related]
7. Facilitated interaction between the pyruvate dehydrogenase kinase isoform 2 and the dihydrolipoyl acetyltransferase.
Hiromasa Y; Roche TE
J Biol Chem; 2003 Sep; 278(36):33681-93. PubMed ID: 12816949
[TBL] [Abstract][Full Text] [Related]
8. Structural basis for the inhibition of PDK2 by novel ATP- and lipoyl-binding site targeting compounds.
Kang J; Pagire HS; Kang D; Song YH; Lee IK; Lee KT; Park CJ; Ahn JH; Kim J
Biochem Biophys Res Commun; 2020 Jun; 527(3):778-784. PubMed ID: 32444142
[TBL] [Abstract][Full Text] [Related]
9. Activation of mitochondrial oxidation by PDK2 inhibition reverses cisplatin resistance in head and neck cancer.
Roh JL; Park JY; Kim EH; Jang HJ; Kwon M
Cancer Lett; 2016 Feb; 371(1):20-9. PubMed ID: 26607904
[TBL] [Abstract][Full Text] [Related]
10. Structural determinants for cross-talk between pyruvate dehydrogenase kinase 3 and lipoyl domain 2 of the human pyruvate dehydrogenase complex.
Tso SC; Kato M; Chuang JL; Chuang DT
J Biol Chem; 2006 Sep; 281(37):27197-204. PubMed ID: 16849321
[TBL] [Abstract][Full Text] [Related]
11. Pyruvate Dehydrogenase Kinase Inhibition by Dichloroacetate in Melanoma Cells Unveils Metabolic Vulnerabilities.
Tiersma JF; Evers B; Bakker BM; Jalving M; de Jong S
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409102
[TBL] [Abstract][Full Text] [Related]
12. Furoates and thenoates inhibit pyruvate dehydrogenase kinase 2 allosterically by binding to its pyruvate regulatory site.
Masini T; Birkaya B; van Dijk S; Mondal M; Hekelaar J; Jäger M; Terwisscha van Scheltinga AC; Patel MS; Hirsch AK; Moman E
J Enzyme Inhib Med Chem; 2016; 31(sup4):170-175. PubMed ID: 27435185
[TBL] [Abstract][Full Text] [Related]
13. The carboxy-terminal tail of pyruvate dehydrogenase kinase 2 is required for the kinase activity.
Klyuyeva A; Tuganova A; Popov KM
Biochemistry; 2005 Oct; 44(41):13573-82. PubMed ID: 16216081
[TBL] [Abstract][Full Text] [Related]
14. Pyruvate dehydrogenase kinase expression and metabolic changes following dichloroacetate exposure in anoxic human colorectal cancer cells.
Ho N; Coomber BL
Exp Cell Res; 2015 Feb; 331(1):73-81. PubMed ID: 25536473
[TBL] [Abstract][Full Text] [Related]
15. Pyruvate dehydrogenase kinase regulatory mechanisms and inhibition in treating diabetes, heart ischemia, and cancer.
Roche TE; Hiromasa Y
Cell Mol Life Sci; 2007 Apr; 64(7-8):830-49. PubMed ID: 17310282
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Targeting of the Pyruvate Dehydrogenase Complex/Pyruvate Dehydrogenase Kinase (PDC/PDK) Axis in Cancer.
Stacpoole PW
J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059435
[TBL] [Abstract][Full Text] [Related]
17. Pyruvate dehydrogenase kinase isoform 2 activity limited and further inhibited by slowing down the rate of dissociation of ADP.
Bao H; Kasten SA; Yan X; Roche TE
Biochemistry; 2004 Oct; 43(42):13432-41. PubMed ID: 15491150
[TBL] [Abstract][Full Text] [Related]
18. Targeting of two aspects of metabolism in breast cancer treatment.
Gang BP; Dilda PJ; Hogg PJ; Blackburn AC
Cancer Biol Ther; 2014; 15(11):1533-41. PubMed ID: 25482950
[TBL] [Abstract][Full Text] [Related]
19. Dichloroacetate induces regulatory T-cell differentiation and suppresses Th17-cell differentiation by pyruvate dehydrogenase kinase-independent mechanism.
Makita N; Ishiguro J; Suzuki K; Nara F
J Pharm Pharmacol; 2017 Jan; 69(1):43-51. PubMed ID: 27757958
[TBL] [Abstract][Full Text] [Related]
20. A novel inhibitor of pyruvate dehydrogenase kinase stimulates myocardial carbohydrate oxidation in diet-induced obesity.
Wu CY; Satapati S; Gui W; Wynn RM; Sharma G; Lou M; Qi X; Burgess SC; Malloy C; Khemtong C; Sherry AD; Chuang DT; Merritt ME
J Biol Chem; 2018 Jun; 293(25):9604-9613. PubMed ID: 29739849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
